You are here

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Last updated on March 22, 2018

FOR MORE INFORMATION
Study Location
K & S Professional Research Services, LLC
Little Rock, Arkansas, 72201 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of schizophrenia with acute exacerbation of illness

- The current acute exacerbation of schizophrenia must be less than 4 weeks duration
prior to the initial evaluation.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with evidence or history of clinically significant uncontrolled medical
illness

- Subjects with a current diagnosis of schizoaffective disorder, major depression,
bipolar disorder, or obsessive compulsive disorder.

- Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic
criteria for psychoactive substance dependence (excluding nicotine dependence) within
12 months of screening or DSM-IV defined substance abuse within 3 months prior to
screening.

NCT01175135
Pfizer
Completed
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Schizophrenia
NCT00579670
All Genders
18+
Years
Multiple Sites
Schizophrenia, Metabolic Syndrome X
NCT00448630
All Genders
18+
Years
Multiple Sites
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
A Phase 2, Multicenter, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of PF-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Schizophrenia
  • Drug: PF-02545920
    5 mg tablet every 12 hours for 28 days
  • Drug: PF-02545920
    15 mg tablet every 12 hours for 28 days
  • Drug: Placebo
    One tablet/capsule every 12 hours for 28 days
  • Drug: Risperidone
    3 mg capsule every 12 hours for 28 days
    Other Name: Risperdal
  • Experimental: PF-02545920 5 mg
    Intervention: Drug: PF-02545920
  • Experimental: PF-02545920 15 mg
    Intervention: Drug: PF-02545920
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Risperidone 3 mg
    Intervention: Drug: Risperidone
Targum SD, Little JA, Lopez E, Demartinis N, Rapaport M, Ereshefsky L. Application of external review for subject selection in a schizophrenia trial. J Clin Psychopharmacol. 2012 Apr;32(2):825-6. doi: 10.1097/JCP.0b013e318248da90.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
259
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of schizophrenia with acute exacerbation of illness
  • The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant uncontrolled medical illness
  • Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.
  • Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Ukraine,   United States
 
 
NCT01175135
A8241012
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now